BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32011034)

  • 21. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
    Guo Y; Fan Y; Pei X
    Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
    Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
    Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
    Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
    Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
    Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
    Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
    Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
    Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
    Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
    J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.
    Zhang Y; Tian J; Qu C; Peng Y; Lei J; Li K; Zong B; Sun L; Liu S
    Breast Cancer; 2021 Jul; 28(4):859-873. PubMed ID: 33569740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
    Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
    Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
    Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
    Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
    Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
    Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
    Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
    Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene.
    Wang YL; Liang RH; Wang CY; Zhang RP; Wu SY; Han X; Zhang GL
    Clin Transl Oncol; 2022 Jan; 24(1):84-92. PubMed ID: 34181232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway.
    Wang L; Kang FB; Wang J; Yang C; He DW
    Anticancer Drugs; 2019 Mar; 30(3):225-232. PubMed ID: 30334817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
    Colín-Val Z; López-Díazguerrero NE; López-Marure R
    J Steroid Biochem Mol Biol; 2021 Apr; 208():105818. PubMed ID: 33508440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.